Latest

Progressive Supranuclear Palsy

·July 17, 2026·12 min read

Tau Buildup in PSP Affects Distant Thinking Brain Networks

Cognitive and behavioral symptoms in Progressive Supranuclear Palsy (PSP) are driven by the remote circuit disruption of a shared frontoparietal architecture called the "PSP-tau network."

Featured Neurology Neuroscience Psychology

·March 24, 2026·9 min read

Depression and Gut Issues Linked to Future PSP

A new study identified five key risk factors for Progressive Supranuclear Palsy (PSP), including depression 10 years pre-diagnosis. The findings suggest the disease develops silently for a decade before motor symptoms appear.

Featured Neurology Neuroscience

·July 22, 2025·6 min read

Synaptic Tau and Astrocytes Drive PSP Progression

ew research uncovers how tau pathology spreads and damages synapses in progressive supranuclear palsy (PSP). Using human postmortem tissue and live brain slice models, scientists showed tau accumulates in both pre- and postsynaptic terminals, likely propagating neuron-to-neuron.

Featured Neurology Neuroscience

·April 30, 2025·5 min read

Skin Test Detects Neurodegenerative Disease PSP with High Accuracy

Researchers have developed a skin-based test that can detect misfolded tau proteins specific to progressive supranuclear palsy (PSP), offering a faster, more accurate diagnosis than current methods. This breakthrough could improve patient assignment to clinical trials and eventually guide targeted, precision treatments.

Featured Neurology Neuroscience

·September 4, 2024·4 min read

Drug Trial Offers Hope for Progressive Supranuclear Palsy

A new clinical trial will test three drugs concurrently to find treatments for progressive supranuclear palsy (PSP), a rare and fatal neurodegenerative disorder. The trial aims to slow the relentless progression of PSP, which currently has no cure.

Featured Neurology Neuroscience

·July 5, 2024·6 min read

Breakthrough in Diagnosing Deadly Brain Disorder PSP

Researchers identified protein biomarkers in spinal fluid that can diagnose progressive supranuclear palsy (PSP) in living patients. Using high-throughput technology, they found a distinct protein pattern in PSP patients, offering hope for early diagnosis and targeted treatments.

Featured Genetics Neurology Neuroscience

·November 3, 2023·5 min read

Promising Targets Discovered for Rare Brain Disorder PSP

Researchers have identified new therapeutic targets for progressive supranuclear palsy (PSP), an incurable brain disorder with symptoms mimicking Parkinson's and dementia. The study focused on RNA sequencing from brain samples of over 400 individuals.

Featured Neurology Neuroscience

·January 6, 2023·4 min read

Inflammatory Trigger a New Clue in Alzheimer’s and PSP

An inflammatory trigger like one present during viral infections is elevated in those with Alzheimer's disease and progressive supranuclear palsy (PSP).

Featured Neurology Neuroscience

·October 13, 2022·5 min read

Memory and Logic Test Detects Dementia Signs up to Nine Years Ahead of Diagnosis

People who later developed Alzheimer's disease scored poorly on memory and logic-based tests, as well as reaction times and grip tests. They were also more likely to have experienced a fall within the past 12 months. Those who developed PSP were twice as likely to experience a fall.

Featured Genetics Neurology Neuroscience

·August 18, 2022·6 min read

New Dementia Risk Genes Identified Through Novel Testing Approach

Researchers have identified multiple new risk genes for Alzheimer's disease and progressive supranuclear palsy (PSP).

Featured Neurology Neuroscience

·April 4, 2022·7 min read

Loss of Neurons, Not Lack of Sleep, Makes Alzheimer’s Patients Drowsy

Degeneration of neurons associated with wakefulness, and not a lack of sleep, makes Alzheimer's patients more drowsy. The degeneration of these neurons is caused by the tau protein. In PSP, the damage to the neurons was associated with symptoms of sleep deprivation.

Featured Neurology Neuroscience Open Neuroscience Articles

·March 19, 2022·5 min read

New Strategy Reduces Brain Damage in PSP, Alzheimer’s, and Related Disorders in Mice

Alpha2-NKA, a protein that drives toxicity in astrocytes, was discovered in higher levels of brain samples from people who died of PSP, Alzheimer's and other tau-related neurodegenerative disorders. Treatment with an FDA-approved drug called digoxin may suppress the inflamed astrocytes and halt disease progression for those with tauopathy disorders.

1 2

Progressive Supranuclear Palsy

Tau Buildup in PSP Affects Distant Thinking Brain Networks

Depression and Gut Issues Linked to Future PSP

Synaptic Tau and Astrocytes Drive PSP Progression

Skin Test Detects Neurodegenerative Disease PSP with High Accuracy

Drug Trial Offers Hope for Progressive Supranuclear Palsy

Breakthrough in Diagnosing Deadly Brain Disorder PSP

Promising Targets Discovered for Rare Brain Disorder PSP

Inflammatory Trigger a New Clue in Alzheimer’s and PSP

Memory and Logic Test Detects Dementia Signs up to Nine Years Ahead of Diagnosis

New Dementia Risk Genes Identified Through Novel Testing Approach

Loss of Neurons, Not Lack of Sleep, Makes Alzheimer’s Patients Drowsy

New Strategy Reduces Brain Damage in PSP, Alzheimer’s, and Related Disorders in Mice

How Severe Illness During Pregnancy Alters Fetal Brain Development

Aging Brains Maintain Robust Language Networks Despite Cognitive Decline

Youth Protein TIMP2 Restores Immune Function in the Aging Brain

Shame, Stigma, and Culture Prevent Male Domestic Violence Survivors From Seeking Help

Subscribe